Levodopa-induced pseudopheochromocytoma
European Journal of Case Reports in Internal Medicine, 2023 Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso +6 more
openaire +3 more sources
Application of Mathematical Models in Drug Release Kinetics of Carbidopa and Levodopa ER Tablets
, 2017 The aim of present work is to determine and analyse the kinetics of drug release from the matrix tablet by employing various mathematical models. A study was done with Carbidopa and Levodopa ER tablets, 50 mg/200 mg by employing wet granulation technique
H. Baishya
semanticscholar +1 more source
Sonolysis of levodopa and paracetamol in aqueous solutions. [PDF]
, 2009 Pharmaceutical products are often present in wastewater treatment effluents, rivers, lakes and, more rarely, in groundwater. The advanced oxidation methods, like ultrasound, find a promising future in the area of wastewater treatment.
Delmas, Henri +4 more
core +1 more source
Levodopa and the progression of Parkinson's disease.
New England Journal of Medicine, 2004 BACKGROUND Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's
S. Fahn +8 more
semanticscholar +1 more source
Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson's disease. [PDF]
, 2018 BackgroundVitamin D (VitD) deficiency is common in Parkinson's disease (PD) and has been raised as a possible PD risk factor. In the past decade, VitD supplementation for potential prevention of age related conditions has become more common.
Christine, Chadwick W +4 more
core +2 more sources
Extended Timed Up and Go assessment as a clinical indicator of cognitive state in Parkinson\u27s disease [PDF]
, 2017 Objective: To evaluate a modified extended Timed Up and Go (extended-TUG) assessment against a panel of validated clinical assessments, as an indicator of Parkinson’s disease (PD) severity and cognitive impairment. Methods: Eighty-seven participants with
Anderton, R +7 more
core +2 more sources
Frontiers in Neurology, 2023 BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki +4 more
doaj +1 more source
Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis [PDF]
, 2010 Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic
Bötzel, Kai +4 more
core +1 more source
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. [PDF]
, 2016 BACKGROUND: Parkinson's disease has been reported in a small number of patients with chromosome 22q11.2 deletion syndrome. In this study, we screened a series of large, independent Parkinson's disease case-control studies for deletions at 22q11.2 ...
Abramov, Andrey Y +38 more
core +3 more sources
Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease [PDF]
Einstein (São Paulo), 2012 Objective: To identify the effect of levodopa in language areas inParkinson’s disease patients. Methods: We evaluated 50 patientswith mild to moderate Parkinson’s disease, age and gender pairedto 47 healthy volunteers.
Paula Ricci Arantes +7 more
doaj